The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The Rituximab in ANCA-Associated Vasculitis (RAVE) trial compared rituximab to cyclophosphamide as induction therapy for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. We undertook the current study to determine whether known single-nucleotide polymorphisms (SNPs) for Fcγ receptors (FcγR) or cytochrome P450 (CYP) enzymes were associated with the response to treatment with rituximab and cyclophosphamide, respectively.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev):

Title: Arthritis & rheumatology (Hoboken, N.J.)

Publisher: Wiley-Blackwell

ISSN (Electronic): 2326-5205

ISSN (Print): 2326-5191

Publication date (Electronic): Jan 2017

Volume: 69

Issue: 1

Affiliations

[1 ] Mayo Clinic and Foundation, Rochester, Minnesota, and Scottsdale, Arizona.

[2 ] Ohio State University, Columbus.

[3 ] Massachusetts General Hospital, Boston.

[4 ] Cleveland Clinic, Cleveland, Ohio.

[5 ] University of Groningen, Groningen, The Netherlands.

[6 ] University of Pennsylvania, Philadelphia.

[7 ] Hospital for Special Surgery, New York, New York.

[8 ] Boston University School of Medicine, Boston, Massachusetts.

[9 ] Duke University Medical Center, Durham, North Carolina.

[10 ] Johns Hopkins University, Baltimore, Maryland.

[11 ] Immune Tolerance Network, San Francisco, California.

[12 ] Genentech, South San Francisco, California.

Article

DOI: 10.1002/art.39822

PubMed ID: 27482943

SO-VID: 17a15a2d-6ebe-455f-bd4e-c6cc358d386f

History

Data availability:

Comments

Comment on this article

scite_

Cited by 9

See all cited by